Skip to content
PodParley
GRACEcast ALL Subjects audio and video podcast artwork

PODCAST · science

GRACEcast ALL Subjects audio and video

by cancerGRACE - H. Jack West, MD

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Publisher-supplied feed metadata · PodParley refreshed Apr 14, 2026 · Source feed

Subscribe · 0 Bookmark

Episodes

  1. Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

    Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

  2. Management of Rare Kidney Tumors

    What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.

  3. Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

    The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

  4. NanoString Treatment for Kidney Cancer

    NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.

  5. Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

    Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

  6. How is the Heng Criteria Applied to Kidney Cancer Patients?

    Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.

  7. Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

    The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

  8. What is PD1 and PDL1 in Kidney Cancer?

    Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.

  9. Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

    The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

  10. No Clear Answer for Non-Clear Cell Kidney Cancer

    Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

  11. What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

    "Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).

  12. Treating Newly Diagnosed Kidney Cancer

    Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.

  13. MET-Amplified Lung Cancer: A New Target for XALKORI?

    Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.

  14. The Hottest Thing in Late Stage Kidney Cancer

    Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.

  15. CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer

    Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.

  16. The Promise of PD1 Inhibitors in Kidney Cancer

    Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.

  17. FGFR and Its Role in Treating Squamous Cell Lung Cancer

    Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

  18. AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer

    EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.

  19. What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?

    "HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

  20. What Is Non-Clear Cell Kidney Cancer?

    Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.

  21. The Promise of Immunotherapy in Lung Cancer

    Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

  22. Does Gilotrif Help EGFR Positive Lung Cancer Patients?

    An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.

  23. Is Progression-Free Survival Meaningful?

    Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?

  24. DDR2 Mutations in Squamous Cell Lung Cancer

    A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

  25. Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?

    Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.

  26. What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?

    Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.

  27. How Do We Make EGFR Inhibitors Work Better for Patients

    Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.

  28. TH 302: New Drug May Make Tumors Less Resistant to Treatment

    Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.

  29. Should We Do Broad Sequencing of All Lung Tumors?

    How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.

  30. How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?

    Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.

  31. Why Are Non-Mutated EGFR Genes Called "Wild Type?"

    When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called "wild type." February 2014.

  32. Teaching the Immune System to Attack Lung Cancer Tumors

    Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center explains how immune therapy works and how it might impact the future of lung cancer treatment.

  33. Advice for Lung Cancer Patients: Know Thy Cancer

    What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they have and which, if any, mutations their lung tumors may have. He explains why in this video.

  34. Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?

    If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal of Stanford University Medical Center discusses the reasons for and against it. February 2014.

  35. Treating EGFR Patients After Tarceva Stops Working

    Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer Center talks about the next generation EGFR inhibitors that may soon become available. February 2014.

  36. Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?

    Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients and whether or not Tarceva (erlotinib) would prevent disease recurrence. February 2014.

  37. An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?

    Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patients are progressing. February 2014.

  38. Targeted Treatment for Lung Cancer After Progression

    Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on those therapies after their cancers begin to grow again. February 2014.

  39. Can Vaccines Fight Lung Cancer?

    Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.

  40. CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients

    Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 2014.

  41. Why Do We Call Them "Small Cell Lung Cancer" and "Non-Small Cell Lung Cancer"?

    Dr. Cathy Pietanza of Memorial Sloan Kettering explains how small cell lung cancer and non-small cell lung cancer are differentiated. February 2014.

  42. Targeting the RAF Pathway in Lung Cancer

    Dr. Charles Rudin of Memorial Sloan Kettering talks about RAF and other genetic mutations that play a role in the growth of lung cancer. February 2014.

  43. Is It Possible to Test Lung Tumors Without Doing a Biopsy?

    Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute talks about exciting new developments which will allow oncologists to test patients' lung tumors without invasive biopsies. February 2014.

  44. What Are PARP Inhibitors, and Might They Improve Outcomes in Small Cell Lung Cancer?

    Dr. Charles Rudin of Memorial Sloan Kettering on how PARP inhibitors may benefit patients with small cell lung cancer. February 2014.

  45. New Insights into Small Cell Lung Cancer

    Dr. Cathy Pietanza of Memorial Sloan Kettering on the new avenues of research into the treatment of small cell lung cancer. February 2014.

  46. In What Clinical Setting Should Immunotherapies Be Developed?

    Dr. Charles Rudin of Memorial Sloan Kettering discusses immune therapies that show promise in fighting lung cancer. February 2014.

  47. Maintenance Therapy in Small Cell Lung Cancer

    Dr. Cathy Pietanza of Memorial Sloan Kettering on current and emerging treatments that are given to help keep small cell lung cancer from coming back after it has disappeared following initial therapy. February 2014.

  48. LDE225 and Small Cell Lung Cancer

    Dr. Cathy Pietanza of Memorial Sloan Kettering talks about a drug currently in clinical trials that may successfully treat small cell lung cancer. February 2014.

  49. Is There a Silver Bullet for Small Cell Lung Cancer?

    Dr. Cathy Pietanza of Memorial Sloan Kettering discusses potential areas of success in the treatment of small cell lung cancer. February 2014.

  50. Advice for Newly Diagnosed Small Cell Lung Cancer Patients

    Dr. Cathy Pietanza of Memorial Sloan Kettering offers suggestions for newly diagnosed small cell lung cancer patients. February 2014.

View all 300 episodes →

Type above to search every episode's transcript for a word or phrase. Matches are scoped to this podcast.

Searching…

We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.

No matches for "" in this podcast's transcripts.

Showing of matches

No topics indexed yet for this podcast.

Loading reviews...

ABOUT THIS SHOW

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

HOSTED BY

cancerGRACE - H. Jack West, MD

Frequently Asked Questions

How many episodes does GRACEcast ALL Subjects audio and video have?

GRACEcast ALL Subjects audio and video currently has 300 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.

What is GRACEcast ALL Subjects audio and video about?

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

How often does GRACEcast ALL Subjects audio and video release new episodes?

GRACEcast ALL Subjects audio and video publishes regularly with 300 episodes available. Check the episode list for the typical release schedule.

Where can I listen to GRACEcast ALL Subjects audio and video?

You can listen to GRACEcast ALL Subjects audio and video on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.

Who hosts GRACEcast ALL Subjects audio and video?

GRACEcast ALL Subjects audio and video is created and hosted by cancerGRACE - H. Jack West, MD.
URL copied to clipboard!